Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
暂无分享,去创建一个
P. Wust | V. Budach | A. Jordan | K. Maier-Hauff | B. Thiesen | H. Orawa | F. Ulrich | D. Nestler | Hendrik Niehoff | Burghard Thiesen
[1] C. Hadjipanayis,et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. , 2010, Cancer research.
[2] Peter Wust,et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.
[3] Jenghwa Chang,et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. , 2009, International journal of radiation oncology, biology, physics.
[4] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[5] R. Labianca,et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2009, Cancer Chemotherapy and Pharmacology.
[6] Karl-Titus Hoffmann,et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. , 2009, Biomaterials.
[7] L. Buie,et al. Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme , 2008, The Annals of pharmacotherapy.
[8] M. Mehta,et al. Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma , 2008, American journal of clinical oncology.
[9] G. Broggi,et al. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? , 2008, Journal of Neuro-Oncology.
[10] R. Warnick,et al. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.
[11] Elizabeth Eisenhauer,et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.
[12] Peter Wust,et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. , 2007, European urology.
[13] G. Reifenberger,et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P Wust,et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[15] A. Brandes,et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.
[16] Hans-Joachim Schwarzmaier,et al. MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. , 2006, European journal of radiology.
[17] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[18] S. Loening,et al. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer , 2006, The Prostate.
[19] Peter Wust,et al. Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme , 2006, Journal of Neuro-Oncology.
[20] Roland Felix,et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma , 2006, Journal of Neuro-Oncology.
[21] C. Rhee,et al. ACNU–cisplatin Continuous Infusion Chemotherapy as Salvage Therapy for Recurrent Glioblastomas: Phase II Study , 2005, Journal of Neuro-Oncology.
[22] A. Olivi,et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. , 2005, International journal of radiation oncology, biology, physics.
[23] K. Bratengeier,et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma , 2005, BMC Cancer.
[24] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[25] J. Debus,et al. Stereotactically Guided Fractionated Re-irradiation in Recurrent Glioblastoma Multiforme , 2005, Journal of Neuro-Oncology.
[26] Peter Wust,et al. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. , 2004, Medical physics.
[27] Susan M. Chang,et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. , 2004, Neuro-oncology.
[28] Susan M. Chang,et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. , 2004, Journal of neurosurgery.
[29] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Raymond Sawaya,et al. Extent of Resection in Malignant Gliomas: a Critical Summary , 2004, Journal of Neuro-Oncology.
[31] U. Bogdahn,et al. Salvage therapy in patients with glioblastoma , 2003, Cancer.
[32] P. Wust,et al. Hyperthermia in combined treatment of cancer. , 2002, The Lancet Oncology.
[33] P. Cornu,et al. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. , 2002, International journal of radiation oncology, biology, physics.
[34] A. Hart,et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial , 2000, The Lancet.
[35] W. Hall,et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. , 1999, International journal of radiation oncology, biology, physics.
[36] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] W. Curran,et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. , 1999, International journal of radiation oncology, biology, physics.
[38] T L Phillips,et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. , 1998, International journal of radiation oncology, biology, physics.
[39] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[40] P. Wen,et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. , 1995, Neurosurgery.
[41] R. Simon,et al. Confidence intervals for reporting results of clinical trials. , 1986, Annals of internal medicine.